ানোSanofi: New analysis of Nirsevimab data supports its effectiveness against RSV MyPharma version

Posted on Wednesday, May 11, 2022 Sanofi announced that the results of a pre-determined analysis of data pooled from the Pivotal Phase III Melody Trial and the Nirsevimab Phase IIb Trial showed an efficacy of 79.5% (95 CI: 65.9 to 87.7) (relative risk reduction compared to placebo);